Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference
Mersana Therapeutics (NASDAQ:MRSN) announced that Anna Protopapas, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:00 a.m. ET. The event will focus on Mersana's pipeline of antibody-drug conjugates (ADCs) targeting high unmet medical needs in cancer treatment.
A live webcast of the presentation can be accessed on Mersana's website. The company is advancing several ADCs, including UpRi, targeting NaPi2b in patients with platinum-resistant ovarian cancer and NSCLC.
- None.
- None.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:00 a.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com
FAQ
When will Mersana Therapeutics present at the Jefferies Virtual Healthcare Conference?
Who is the CEO of Mersana Therapeutics?
What is the focus of Mersana Therapeutics' presentation?
How can I watch the Mersana Therapeutics presentation?
What is the lead product candidate of Mersana Therapeutics?
